Medications often have unwanted side-effects. One reason is that they reach not only the unhealthy cells for which they are intended, but also reach and have an impact on healthy cells. Researchers at the Technical University of Munich (TUM), working together with the KTH Royal Institute of ... more
Prof. Dr. Arne Skerra
Technische Universität München, Lehrstuhl für Biologische Chemie
Arne Skerra, born in 1961, studied chemistry at the Technical University of Darmstadt and obtained his doctoral degree as Dr. rer. nat. at the Gene Center of the Ludwig-Maximilians University Munich in 1989. After staying at the MRC Laboratory of Molecular Biology in Cambridge, UK, and the Max-Planck-Institute for Biophysics in Frankfurt/Main, he became professor for protein chemistry in Darmstadt in 2004. Since 1998, he has been full professor and head of the biological chemistry institute at the TU Munich in Weihenstephan. Apart from his commitment in scientific societies, e.g. as chairman of the biochemistry division of GDCh, Skerra is also an entrepreneur. His process for the production of functional antibody fragments in E. coli by genetic engineering as well as the Strep-tag protein affinity tag are applied world-wide today. In 2001, he founded Pieris AG, which commercializes and develops Anticalins as a new class of biopharmaceuticals. Furthermore, in 2009 he founded XL-protein GmbH based on the PASylation technology to extend the plasma half-life of biologics.